D. S. Belkina

D. S. Belkina

Auto-generated profile, based on publicly available information

D. S. Belkina

National Medical Research Center for Hematology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Clinical oncohematology
Verified
Journal Article
Open access
PDF file
YMYana Konstantinovna Mangasarova
Yana Konstantinovna Mangasarova
RAR. R. Abdurashidova
R. R. Abdurashidova
AMAminat Umaraskhabovna Magomedova
Aminat Umaraskhabovna Magomedova
OMO. V. Margolin
O. V. Margolin
ENE. S. Nesterova
E. S. Nesterova
EZE. E. Zvonkov
E. E. Zvonkov
BACKGROUND. Up to now, neither the optimal treatment regimen for primary mediastinal large B-cell lymphoma (PMBCL), nor poor/favorable prognostic factors for risk stratification at the disease onset have been found. The prognosis of PMBCL is determined by the depth of metabolic response by the time of treatment completion, which underlies a response-adapted strategy. Besides, PMBCL is an aggressive tumor occurring more commonly in young women of reproductive age, which requires the development of treatment strategy during pregnancy. AIM. To assess the efficacy of the response-adapted strategy in PMBCL treatment based on the DA-EPOCH-R program in remission induction with drug dose escalation and without subsequent radiotherapy, if a complete metabolic response is reported by PET-CT. MATERIALS & METHODS. This prospective single-center clinical trial enrolled 154 patients in the period from November 2012 to March 2023. The median age of the patients was 34 years (range 19–68 years). There were 51 (33.1 %) men and 103 (66.9 %) women, 11 of whom were at various gestational ages of pregnancy. RESULTS. The response-adapted treatment was completed in all 154 patients. Overall response was 93.5 % (144/154), complete remission was 78.6 % (121/154), and partial remission was 14.9 % (23/154). Progression was reported in 6.5 % (10/154) of patients. With a follow-up of 60 months, the overall, disease-free, progression-free, and event-free survival rates were 93 %, 98 %, 92 %, and 76 %, respectively. The median was not reached. Prior to chemotherapy, 11 pregnant women aged 21–37 (median 29 years) had been assessed. By the time of PMBCL diagnosis, the gestational age of them varied from 9 to 37 weeks (median 26 weeks). Immunochemotherapy was administered to 9 women during pregnancy. At the gestational age of 27–38 weeks (median 34 weeks) delivery was reported in 10 patients who gave birth to 11 children. The children showed no malformations. All women with PMBCL diagnosed during pregnancy and all their children had been followed-up by the time of this publication. CONCLUSION. The response-adapted strategy of PMBCL treatment with the DA-EPOCH-R regimen and drug dose escalation showed a high immediate and long-term efficacy as well as tolerable toxicity, which provided ground for the decision against radiotherapy, if a complete metabolic response was reported by PET-CT. The results of this trial establish the main goal of treating aggressive lymphomas during pregnancy which is saving of two lives. Delivery of newborns without malformations despite immunochemotherapy justifies the use of the DA-EPOCH-R program at the gestational age > 12 weeks.

10 December 2025 in Oncohematology
Verified
Journal Article
Open access
PDF file
RAR. R. Abdurashidova
R. R. Abdurashidova
YMYa. K. Mangasarova
Ya. K. Mangasarova
ASA. A. Sadreeva
A. A. Sadreeva
KAK. A. Akezheva
K. A. Akezheva
DBD. S. Belkina
D. S. Belkina
OAOlga Aleshina
Olga Aleshina
In patients with aggressive, rapidly progressive B-cell non-Hodgkin lymphomas (NHL), the waiting window between leukapheresis and infusion of chimeric antigen receptor (CAR) T-cells carries a risk of clinical deterioration, disease progression, and dropout from therapy. Bridging therapy (BT) aims to maintain disease control until infusion and to reduce tumor burden – factors that are both associated with improved outcomes after CAR T-cell therapy. Despite the wide range of approaches used (radiation therapy, polatuzumab-based regimens, bispecific antibodies, Bruton’s tyrosine kinase inhibitors, and glucocorticoids), BT is prescribed at the discretion of the attending physician. Aim – to systematize available data on the efficacy and safety of different BT options and to assess their impact on outcomes of CAR T-cell therapy in non-Hodgkin lymphomas. Bridging therapy is defined as any antitumor therapy administered after leukapheresis and before lymphodepletion with the goal of stabilizing disease or reducing tumor burden prior to CAR T-cell infusion.

23 March 2026 in Oncohematology
Verified
Journal Article
Open access
ENEkaterina Nesterova
Ekaterina Nesterova
YMY. K. Mangasarova
Y. K. Mangasarova
III. L. Israilova
I. L. Israilova
AMAminat Umaraskhabovna Magomedova
Aminat Umaraskhabovna Magomedova
MBM. O. Bagova
M. O. Bagova
EPE. N. Parovichnikova
E. N. Parovichnikova
Background. In Russian clinical practice, there is no systematic information on patients with follicular lymphoma (FL) relapses after first-line therapy, and only isolated data are presented regarding the frequency of early and late relapses in the domestic population, first-line therapy regimens used in these patients, the dynamics of treatment response, timing of relapse, and second-line therapy regimens. A detailed analysis of a large cohort of patients with relapsed FL, including detailed clinical, laboratory, morphoimmunohistochemical, and molecular genetic characteristics, the treatments administered at onset and during relapse, as well as the identification of factors correlating with the risk of early progression, is of great scientific and practical interest. This is the focus of this study. Our results will be aimed at optimizing treatment and improving the prognosis of FL patients in Russia who have received second-line therapy. Aim. To describe changes in the therapeutic landscape of first-line FL therapy from 2001 to 2025 for patients receiving treatment at the National Medical Research Center for Hematology; to analyze the effectiveness of the therapeutic protocols used; to study cases of treatment resistance and identify significant factors influencing the prognosis of the disease; as well as to determine outcomes for patients with the first early relapse of nodal FL. Materials and methods. A retrospective and prospective study conducted from 2001 to 2025 at the National Medical Research Center of Hematology (Moscow) included 445 patients with newly diagnosed FL of cytological types 1–2 and 3A (World Health Organization, 2017). The median follow-up was 95 (1–251) months. All patients were treated according to the criteria of the Groupe d’Etude des Lymphomes Folliculaires. All patients included in the study were divided into two groups: those who received initial treatment between 2001 and 2022 (the historical control group; n = 374) and those who received initial treatment between 2022 and 2025 according to the new FL-2022 risk-based differentiated treatment protocol for patients with nodal FL (n = 71). Data for the two groups were analyzed separately. Results. With a median follow-up of 98 (1–251) months, the 2-year, 5-year, and 10-year overall survival of 374 patients from the historical control group (2001–2022) were 93, 90, and 85 %, respectively; 2-year, 5-year, and 10-year event-free survival were 82, 71, and 55 %, respectively. With high-dose chemotherapy, compared with standard regimens, the proportion of progressions / relapses was significantly lower (26 % versus 40 %; p = 0.01), but if events occurred, they were predominantly early (72 % versus 58 %; p = 0.2). According to the results of multivariate analysis, independent prognostic risk factors for disease progression within 24 months after the start of therapy (POD24) were identified: absence of BCL2 gene rearrangement (odds ratio 3.52 (1.89–6.55); p 0.0001) and 3A cytological type (odds ratio 3.8 (1.61–0.16); p = 0.0033). During second-line therapy in the first early relapse / progression after R-B (rituximab + bendamustine), R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone) and autologous hematopoietic stem cell transplantation, complete remission was achieved in only 38 % of patients, and after R-DHAP it was not achieved in any case. With therapy according to the FL-2022 protocol (2022–2025), with a median follow-up of 23 months, 2-year overall survival was 100 %, 2-year event-free survival was 97 %. Second-line therapy was required in only 6 % of patients. Conclusion. The development of early relapse / progression has a critical impact on the survival prognosis of FL patients. The use of a differentiated treatment protocol for patients with nodal FL (FL-2022), based on clinical, morphological, immunohistochemical, and genetic prognostic factors, has significantly improved treatment outcomes and reduced the risk of POD24. When FL first relapses, there is no uniform treatment standard, and the regimens used vary greatly. Treatment outcomes in the first relapse remain modest, especially for the high-risk POD24 group, necessitating a change in the treatment paradigm for this patient group.

17 July 2026 in Russian journal of hematology and transfusiology
Verified
Journal Article
Open access
PDF file
NPN. P. Podrezov
N. P. Podrezov
EFE. A. Fastova
E. A. Fastova
IKI. V. Krasilnikova
I. V. Krasilnikova
DBD. S. Belkina
D. S. Belkina
MGM. S. Gulieva
M. S. Gulieva
EZE. E. Zvonkov
E. E. Zvonkov
Introduction . Classical Hodgkin lymphoma (cHL) is predominantly diagnosed in women of reproductive age. The expanding use of PD-1 inhibitors in the treatment of cHL increases the likelihood of pregnancy being detected during immunotherapy. However, only a limited number of such observations have been described in the literature, which complicates the choice of an optimal management strategy for these patients. Aim : to present two clinical case reports of patients with cHL: in the first, the beginning of pregnancy (4 weeks) occurred during nivolumab exposure; in the other patient, nivolumab was administered during the periconceptional period, 6 weeks before conception. Main Findings . In the first case, pregnancy was diagnosed at 6 weeks of gestation during maintenance therapy with nivolumab 40 mg every 2 weeks (cumulative dose 600 mg); the last dose was administered at 4 weeks of gestation, and treatment was discontinued after pregnancy was confirmed. Spontaneous delivery occurred at 38 weeks: a boy, birth weight 2910 g, length 49 cm, Apgar scores 8 and 9. In the second case, pregnancy was diagnosed at 3 weeks of gestation after completion of the Nivo-DHAP course with nivolumab at a dose of 240 mg. After pregnancy was confirmed, antitumor treatment was discontinued. Delivery at 38 weeks: cesarean section, a girl, birth weight 3000 g, length 52 cm, Apgar scores 8 and 9. The presented clinical case reports add to the limited clinical data on the course of pregnancy during the use of PD-1 inhibitors and highlight the need for multidisciplinary management and individualized decision-making, taking into account the potential risks to the mother and the fetus.

26 August 2026 in Russian Bulletin of Obstetrician-Gynecologist
Verified
Journal Article
Closed access
IKI.V. Krasilnikova
I.V. Krasilnikova
YMYa.K. Mangasarova
Ya.K. Mangasarova
MBM.O. Bagova
M.O. Bagova
EFE.A. Fastova
E.A. Fastova
ENEkaterina Nesterova
Ekaterina Nesterova
EPE.N. Parovichnikova
E.N. Parovichnikova
Lymphoproliferative diseases are the third most common type of malignant neoplasms detected in pregnant patients. The high effectiveness of the therapy of such patients makes it relevant to study the long-term results of their treatment, as well as the health status of their children. Objective. To present the features of the course of pregnancy and its outcomes in patients with an identified lymphoproliferative disease during pregnancy, to evaluate the long-term effects of the treatment, as well as to analyze the physical development of children born to mothers with lymphoma, at birth and in the catamnesis. Materials and methods. From 2009 to 2025, 44 patients with a diagnosis of lymphoproliferative disease during pregnancy were treated at the Federal State Budgetary Institution “NMRC of Hematology” of the Ministry of Health of the Russian Federation. 28 (64%) pregnant women were diagnosed with non-Hodgkin’s lymphoma, 16 (36%) with Hodgkin’s lymphoma. Among 44 patients, 36 (82%) underwent chemotherapy during pregnancy, in 8 (18%), treatment was postponed until delivery. The median age of the patients at the time of the disease detection was 30 (range 20-39) years. In this retrospective single-center cohort study, we analyzed the development of 46 children born to 44 patients with detected lymphoma during gestation. Results. 43 (98%) of the 44 patients have been alive and are in remission of the disease with a median observation of 56 (range 2-186) months. 30 (68%) patients achieved complete remission after the first line of therapy. The remaining 14 (32%) patients required a second and subsequent line of treatment due to failure of the initial therapy. 6 (14%) cases of disease progression were registered during chemotherapy. Early relapses (1 year) — in 1 (2%) case. One patient died in the late postpartum period from septic complications after high-dose chemotherapy due to the progression of the disease. The median gestational age of newborns was 36 (range 26-40) weeks, 27 of 46 children (61%) were born prematurely. 22 newborns (49%) required follow-up in the intensive care unit. Congenital malformations of the cardiovascular system were detected in 2 babies (4%): 1 case (2%) of an open ductus arteriosus and 1 case (2%) of an interventricular septal defect. However, none of the identified pathological conditions required surgical intervention. At the time of the study, the median age of the children was 5.0 (range 0.3—15.3) years. The following LEN organs diseases were diagnosed later for 11 months among 46 children : adenoid hypertrophy — n=4 (9%), tonsillitis — n= 1 (2%), laryngitis — n=3 (7%), otitis media — n=3 (7%). One child (2%), whose mother did not receive chemotherapy during pregnancy, was diagnosed with cerebral palsy in the first year of life. Conclusion. Despite the diagnostic and therapeutic difficulties in verifying lymphoproliferative diseases during pregnancy, as well as the high frequency of premature birth, long-term catamnesis observations demonstrate favorable outcomes. The patients have long-term remissions, and the condition of their children is satisfactory in most cases.